Esther Obeng, MD

“Targeting SF3B1 in myelodysplastic syndrome”

Myelodysplastic syndromes (MDS) are a group of pre-leukemia blood disorders with a high risk of progression to aggressive leukemia, SF3B1 mutations are frequent, early events in MDS pathogenesis and ideal therapeutic targets. The proposed studies will evaluate how SF3B1 mutations cause MDS and test novel agents in SF3B1-mutant cells.